Brief: Herantis Announces Topline Results Of Phase 1-2 CDNF Trial

Herantis Pharma Oyj

25/02/2020 07:03

Feb 25 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA PLC ANNOUNCES TOPLINE RESULTS OF PHASE 1-2
CDNF
TRIAL
    * HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE
SAFETY
AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE
PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY
PET IMAGING IN SOME PATIENTS
    * HERANTIS PHARMA OYJ - RESULTS FROM SECOND PART OF TRIAL,
IN
WHICH ALL PATIENTS WILL RECEIVE CDNF FOR AN ADDITIONAL SIX
MONTHS, ARE EXPECTED IN Q3 2020

Source text for Eikon:  ID:nWkr911h70 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))